Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-25T04:31:57.677Z Has data issue: false hasContentIssue false
  • English
  • Français

Introduction to the Guideline, and General Principles of Acute Migraine Management

Published online by Cambridge University Press:  01 July 2015

Irene Worthington ,
Tamara Pringsheim ,
Marek J. Gawel ,
Jonathan Gladstone ,
Paul Cooper ,
Esma Dilli ,
Michel Aube ,
Elizabeth Leroux ,
Werner J. Becker  and
on behalf of the Canadian Headache Society Acute Migraine Treatment Guideline Development Group
Irene Worthington
Affiliation:
Sunnybrook Health Sciences Centre, Toronto, Ontario
Tamara Pringsheim
Affiliation:
University of Calgary and the Hotchkiss Brain Institute, Calgary, Alberta
Marek J. Gawel
Affiliation:
Sunnybrook Health Sciences Centre, Toronto, Ontario Rouge Valley Health System - Centenary, Toronto, Ontario Women's College Hospital, Toronto, Ontario, Canada
Jonathan Gladstone
Affiliation:
Sunnybrook Health Sciences Centre, Toronto, Ontario Gladstone Headache Clinic, Toronto, Ontario
Paul Cooper
Affiliation:
University of Western Ontario, London, Ontario
Esma Dilli
Affiliation:
University of British Columbia, Vancouver, British Columbia
Michel Aube
Affiliation:
McGill University, Montreal, Quebec
Elizabeth Leroux
Affiliation:
University of Montreal, Montreal, Quebec
Werner J. Becker*
Affiliation:
University of Calgary and the Hotchkiss Brain Institute, Calgary, Alberta
*
Division of Neurology, 12th Floor, Foothills Hospital, 1403 29th St NW, Calgary, Alberta, T2N 2T9, Canada
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objectives:

To provide an overview of the objectives and target population of the guideline, and to review the general principles of acute pharmacological migraine therapy.

Methods:

A general literature review and several consensus groups were used to formulate an expert consensus for the general use of acute migraine medications.

Results:

The objective of the guideline is to assist the physician in choosing an appropriate acute migraine medication for an individual with migraine, and thereby to reduce migraine-related disability. The target population includes adults with episodic migraine (patients with migraine headache < 15 days/month). This guideline is intended primarily for physicians who treat patients with migraine. Other health professionals may also find this guideline helpful. Acute migraine therapy should be considered for the great majority of patients with migraine. A specific acute medication is chosen based on evidence for efficacy, tolerability, migraine attack severity, patient preference, and on the presence of co-existing disorders. General principles of acute migraine therapy include that the response of a patient to any given medication cannot be predicted with certainty, and that treatment early in the attack is generally more effective than treatment later once the migraine attack is fully developed. A suitable treatment approach (stratified or stepped approaches) and drug formulation (injection, tablet, wafer, powdered formulation, or nasal spray) should be chosen based on patient clinical features. Excessively frequent use of acute medications (medication overuse) should be avoided. Two or more acute medications can be combined if necessary.

Conclusions:

This guideline provides evidence-based advice on the use of acute medications for migraine, and should provide useful guidance for acute migraine therapy to both health professionals and patients.

Type
SECTION I
Information
Canadian Journal of Neurological Sciences , Volume 40 , Issue S3 , September 2013 , pp. S4 - S9
Copyright
Copyright © The Canadian Journal of Neurological 2014

References

1.Becker, WJ, Gladstone, JP, Aube, M.Migraine prevalence, diagnosis, and disability. Can J Neurol Sci. 2007;34:S3–9.Google ScholarPubMed
2.Cooke, LJ, Becker, WJ.Migraine prevalence, treatment and impact: the Canadian women and migraine study. Can J Neurol Sci. 2010;37:580–7.CrossRefGoogle ScholarPubMed
3.O’Brien, B, Goeree, R, Streiner, D.Prevalence of migraine headache in Canada: a population-based survey. Int J Epidemiol. 1994;23: 1020–6.CrossRefGoogle Scholar
4.Pryse-Phillips, W, Findlay, H, Tugwell, P, Edmeads, J, Murray, TJ, Nelson, RF.A Canadian population survey on the clinical, epidemiologic and societal impact of migraine and tension-type headache. Can J Neurol Sci. 1992;19:333–9.CrossRefGoogle ScholarPubMed
5.Becker, WJ, Christie, SN, Mackie, G, Cooper, P, Canadian Headache Society Migraine Strategy Task, Force. Consensus statement: the development of a national Canadian Migraine Strategy. Can J Neurol Sci. 2010;37:449–56.CrossRefGoogle ScholarPubMed
6.Leonardi, M, Steiner, TJ, Scher, AT, Lipton, RB.The global burden of migraine: measuring disability in headache disorders with WHO’s Classification of Functioning, Disability and Health (ICF). J Headache Pain. 2005;6:429–40.CrossRefGoogle ScholarPubMed
7.Pryse-Phillips, WE, Dodick, DW, Edmeads, JG, et al.Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. [see comment] [erratum appears in CMAJ 1997 Nov 15;157(10):1354]. [Review] [160 refs]. CMAJ. 1997;156:1273–87.Google Scholar
8.Headache Classification Subcommittee of the International Headache, Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24:9–160.Google Scholar
9.Lipton, RB, Stewart, WF, Diamond, S, Diamond, ML, Reed, M.Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41: 646–57.CrossRefGoogle ScholarPubMed
10.Sauro, KM, Becker, WJ.Multidisciplinary treatment for headache in the Canadian healthcare setting. Can J Neurol Sci. 2008;35: 46–56.CrossRefGoogle ScholarPubMed
11.Rains, JC, Penzien, DB, McCrory, DC, Gray, RN.Behavioral headache treatment: history, review of the empirical literature, and methodological critique. Headache. 2005;45:S92–109.CrossRefGoogle ScholarPubMed
12.Pringsheim, T, Davenport, WJ, MacKie, G, et al.Introduction to the guideline, and general principles of migraine prophylaxis - Section i. Can J Neurol Sci. 2012;39:S3–7.Google Scholar
13.Becker, WJ, Gawel, M, Mackie, G, South, V, Christie, SN.Migraine treatment. Can J Neurol Sci. 2007;34:S10–9.Google ScholarPubMed
14.Burstein, R, Cutrer, MF, Yarnitsky, D.The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain. 2000;123:1703–9.CrossRefGoogle ScholarPubMed
15.Moschiano, F, D’Amico, D, Allais, G, et al.Early triptan intervention in migraine: an overview. [Review] [20 refs]. Neurol Sci. 2005;26:s108–10.CrossRefGoogle Scholar
16.Lipton, RB, Stewart, WF, Stone, AM, Lainez, MJ, Sawyer, JP, Disability in Strategies of Care Study, Group. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial. [see comment]. JAMA. 2000;284:2599–605.CrossRefGoogle Scholar
17.Lipton, RB, Bigal, ME, Amatniek, JC, Stewart, WF.Tools for diagnosing migraine and measuring its severity. Headache 2004;44:387–98.CrossRefGoogle ScholarPubMed
18.Lipton, RB, Stewart, WF, Sawyer, J, Edmeads, JG.Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache. 2001; 41:854–61.CrossRefGoogle ScholarPubMed
19.Williams, P, Dowson, AJ, Rapoport, AM, Sawyer, J.The cost effectiveness of stratified care in the management of migraine. Pharmacoeconomics. 2001;19:819–29.CrossRefGoogle ScholarPubMed
20.Silberstein, SD.Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:754–62.CrossRefGoogle Scholar
21.Evers, S, Afra, J, Frese, A, et al.EFNS guideline on the drug treatment of migraine - report of an EFNS task force. Eur J Neurol 2006;13:560–72.Google ScholarPubMed
22.Evers, S, Afra, J, Frese, A, et al.EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol. 2009;16:968–81.CrossRefGoogle ScholarPubMed
23.Gladstone, JP, Gawel, M.Newer formulations of the triptans: advances in migraine management. [Review] [116 refs]. Drugs. 2003;63:2285–305.CrossRefGoogle Scholar
24.Rapoport, AM, Tepper, SJ, Bigal, ME, Sheftell, FD.The triptan formulations : how to match patients and products. [Review] [75 refs]. CNS Drugs. 2003;17:431–47.CrossRefGoogle Scholar
25.Anonymous. Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group. N Engl J Med. 1991;325:316–21.CrossRefGoogle Scholar
26.Tfelt-Hansen, P, De Vries, P, Saxena, PR.Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000;60:1259–87.CrossRefGoogle Scholar
27.Gawel, MJ, Worthington, I, Maggisano, A.A systematic review of the use of triptans in acute migraine.[see comment]. [Review] [74 refs]. Can J Neurol Sci. 2001;28:30–41.CrossRefGoogle Scholar
28.Gawel, M, Worthington, I.Intranasal zolmitriptan. Expert Opin Pharmacother. 2005;6:1019–24.CrossRefGoogle ScholarPubMed
29.Rapoport, A, Winner, P.Nasal delivery of antimigraine drugs: clinical rationale and evidence base. Headache. 2006;46:S192–201.CrossRefGoogle ScholarPubMed
30.Johnston, MM, Rapoport, AM.Triptans for the management of migraine. Drugs. 2010;70:1505–18.CrossRefGoogle ScholarPubMed
31.Yates, R, Sörensen, J, Bergström, M, et al.Distribution of intranasal C-zolmitriptan assessed by positron emission tomography. Cephalalgia. 2005 Dec;25(12):1103–9.CrossRefGoogle ScholarPubMed
32.Kagedal, M, Zingmark, P-, Hedlund, C, Yates, R.True nasopharyngeal absorption of zolmitriptan after administration via nasal spray in healthy male volunteers. American Journal of Drug Delivery. 2005;3:133–40.CrossRefGoogle Scholar
33.Dodick, D, Freitag, F.Evidence-based understanding of medication-overuse headache: clinical implications. Headache. 2006;46: S202–11.CrossRefGoogle ScholarPubMed
34.Tepper, SJ, Tepper, DE.Breaking the cycle of medication overuse headache. Cleve Clin J Med. 2010;77:236–42.CrossRefGoogle ScholarPubMed
35.Evers, S, Marziniak, M.Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurology. 2010;9:391–401.CrossRefGoogle ScholarPubMed
36.Silberstein, SD, Olesen, J, Bousser, MG, et alInternational Headache Society. The International Classification of Headache Disorders, 2nd Edition (ICHD-II)-revision of criteria for 8.2 Medication-overuse headache. Cephalalgia. 2005;25:460–5.CrossRefGoogle Scholar
37.Headache Classification Committee. Olesen, J, Bousser, MG, Diener, HC, et al.New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006;26:742–6.CrossRefGoogle ScholarPubMed
38.Lipton, RB, Hamelsky, SW, Dayno, JM.What do patients with migraine want from acute migraine treatment? Headache. 2002; 42:3–9.CrossRefGoogle ScholarPubMed